title: Long-term growth outcomes in children treated for chronic hepatitis C.
abstract: Effects on linear growth were noted in children treated with peginterferon ± ribavirin in the Pediatric Study of Hepatitis C trial. Growth was further examined in a subset of patients followed for up to 6 years post-treatment. No long-term effects on height-for-age z scores were observed that could be attributed to hepatitis C virus treatment.
authors.affiliation: Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA. Electronic address: maureen.jonas@childrens.harvard.edu.
authors.forename: Maureen M
authors.initials: MM
authors.lastname: Jonas
authors.affiliation: Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins Children's Center, Baltimore, MD.
authors.forename: Kathleen B
authors.initials: KB
authors.lastname: Schwarz
authors.affiliation: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, UF Health Children's Hospital, Gainesville, FL.
authors.forename: Regino
authors.initials: R
authors.lastname: Gonzalez-Peralta
authors.affiliation: Department of Pediatrics and Internal Medicine, NY Presbyterian Hospital, Morgan Stanley Children's Hospital, New York, NY.
authors.forename: Steven
authors.initials: S
authors.lastname: Lobritto
authors.affiliation: Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Riley Hospital for Children, Indianapolis, IN.
authors.forename: Jean P
authors.initials: JP
authors.lastname: Molleston
authors.affiliation: Division of Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA.
authors.forename: Karen F
authors.initials: KF
authors.lastname: Murray
authors.affiliation: Departments of Pediatrics and Surgery, UCSF Benioff Children's Hospital, San Francisco, CA.
authors.forename: Philip
authors.initials: P
authors.lastname: Rosenthal
authors.affiliation: Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Wen
authors.affiliation: Roche Products Limited, Welwyn Garden City, United Kingdom.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Wat
authors.affiliation: Roche Products Limited, Welwyn Garden City, United Kingdom.
authors.forename: Vedran
authors.initials: V
authors.lastname: Pavlovic
authors.affiliation: Roche Products Limited, Welwyn Garden City, United Kingdom.
authors.forename: Charles
authors.initials: C
authors.lastname: Warne
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001827:Body Height / Q000187:drug effects*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha; D008297:Male; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a